Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALPN |
---|---|---|
09:32 ET | 24430 | 64.955 |
09:34 ET | 5658 | 64.955 |
09:36 ET | 10194 | 64.95 |
09:38 ET | 2000 | 64.95 |
09:39 ET | 3500 | 64.955 |
09:41 ET | 1803 | 64.955 |
09:43 ET | 400 | 64.95 |
09:45 ET | 4203 | 64.955 |
09:48 ET | 2998 | 64.96 |
09:50 ET | 53363 | 64.96 |
09:52 ET | 500 | 64.96 |
09:54 ET | 11975 | 64.965 |
09:56 ET | 500 | 64.97 |
09:57 ET | 1900 | 64.97 |
09:59 ET | 6919 | 64.97 |
10:01 ET | 715 | 64.97 |
10:03 ET | 25421 | 64.97 |
10:06 ET | 5250 | 64.97 |
10:08 ET | 2023 | 64.97 |
10:10 ET | 1207 | 64.97 |
10:12 ET | 600 | 64.97 |
10:14 ET | 1097 | 64.97 |
10:15 ET | 1427 | 64.965 |
10:17 ET | 1300 | 64.97 |
10:19 ET | 100 | 64.965 |
10:21 ET | 400 | 64.97 |
10:24 ET | 900 | 64.97 |
10:26 ET | 17453 | 64.98 |
10:28 ET | 1600 | 64.975 |
10:30 ET | 400 | 64.975 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Alpine Immune Sciences Inc | 4.5B | -95.0x | --- |
Krystal Biotech Inc | 4.7B | 87.0x | --- |
Immunovant Inc | 4.5B | -16.9x | --- |
Madrigal Pharmaceuticals Inc | 4.5B | -9.2x | --- |
Nuvalent Inc | 4.6B | -30.4x | --- |
Crinetics Pharmaceuticals Inc | 4.0B | -13.4x | --- |
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.5B |
---|---|
Revenue (TTM) | $56.5M |
Shares Outstanding | 68.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.84 |
EPS | $-0.68 |
Book Value | $5.43 |
P/E Ratio | -95.0x |
Price/Sales (TTM) | 78.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -90.86% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.